ClinicalTrials.gov record
Terminated Phase 2 Interventional

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

ClinicalTrials.gov ID: NCT01373086

Public ClinicalTrials.gov record NCT01373086. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 6:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Proof-of-concept Study to Evaluate the Efficacy and Safety of LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

Study identification

NCT ID
NCT01373086
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
19 participants

Conditions and interventions

Conditions

Interventions

  • Eplerenone Drug
  • LFF269 Drug
  • Placebo Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 30, 2011
Primary completion
Sep 30, 2011
Completion
Sep 30, 2011
Last update posted
Dec 16, 2020

2011

United States locations

U.S. sites
11
U.S. states
7
U.S. cities
10
Facility City State ZIP Site status
Advanced Clinical Research Institute-Phase I Anaheim California 92801
Comprehensive Phase I Fort Myers Florida 333901
Comprehensive Phase One®, Miramar Florida 33025
Comprehensive NeuroScience St. Petersburg Florida 33716
Clinical Research Atlanta Stockbridge Georgia 30281
Clinical Research Advantage/ Prairie Fields Family Medicine, PC Fremont Nebraska 68025
Internal Medicine Physicians Omaha Nebraska 68130
ICON Developmental Solutions Omaha Nebraska 68154
Clinical Research Advantage/ Aloha Medical Las Vegas Nevada 89183
ICON Development Solutions, San Antonio Texas 78209
Comprehensive Clinical Development NW, Inc. Tacoma Washington 98418

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01373086, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 16, 2020 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01373086 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →